Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mustafa Khasraw

Showing results (101-110 of 176) with videos related to

Pageof 18
Sort By:
Asia-Pacific Journal of Clinical Oncology|December 15, 2021
Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and IndiaSherene Loi, Christos S Karapetis, Nicole McCarthy, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2016
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trialsBob T Li, Tristan A Barnes, David L Chan, et al.
Asia-Pacific Journal of Clinical Oncology|June 24, 2021
Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspectiveBenjamin Y Kong, Candace Carter, Anna K Nowak, et al.
Neuro-Oncology Practice|March 18, 2024
Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant gliomaKatherine B Peters, Candice Alford, Amy Heltemes, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 11, 2026
BRCA1-A and LIG4 complexes mediate ecDNA biogenesis and cancer drug resistanceOliver W Chung, Shun Yao, Ling Wang, et al.
Neuro-Oncology|July 3, 2016
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignanciesSarah T Garber, Yuuri Hashimoto, Shiao-Pei Weathers, et al.
The Lancet. Oncology|March 29, 2023
Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials ConferenceRifaquat Rahman, Mei-Yin C Polley, Laura Alder, et al.
Cold Spring Harbor Molecular Case Studies|January 4, 2020
Molecular and clonal evolution in recurrent metastatic gliosarcomaKevin J Anderson, Aaron C Tan, Jonathon Parkinson, et al.
Nature Communications|October 30, 2022
Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastomaWilliam H Tomaszewski, Jessica Waibl-Polania, Molly Chakraborty, et al.
Theranostics|April 25, 2017
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic SignificanceDavid Lh Chan, Nick Pavlakis, Geoffrey P Schembri, et al.
Pageof 18

Showing results (101-110 of 176) with videos related to

Sort By:
Pageof 18
Asia-Pacific Journal of Clinical Oncology|December 15, 2021
Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and IndiaSherene Loi, Christos S Karapetis, Nicole McCarthy, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2016
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trialsBob T Li, Tristan A Barnes, David L Chan, et al.
Asia-Pacific Journal of Clinical Oncology|June 24, 2021
Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspectiveBenjamin Y Kong, Candace Carter, Anna K Nowak, et al.
Neuro-Oncology Practice|March 18, 2024
Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant gliomaKatherine B Peters, Candice Alford, Amy Heltemes, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 11, 2026
BRCA1-A and LIG4 complexes mediate ecDNA biogenesis and cancer drug resistanceOliver W Chung, Shun Yao, Ling Wang, et al.
Neuro-Oncology|July 3, 2016
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignanciesSarah T Garber, Yuuri Hashimoto, Shiao-Pei Weathers, et al.
The Lancet. Oncology|March 29, 2023
Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials ConferenceRifaquat Rahman, Mei-Yin C Polley, Laura Alder, et al.
Cold Spring Harbor Molecular Case Studies|January 4, 2020
Molecular and clonal evolution in recurrent metastatic gliosarcomaKevin J Anderson, Aaron C Tan, Jonathon Parkinson, et al.
Nature Communications|October 30, 2022
Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastomaWilliam H Tomaszewski, Jessica Waibl-Polania, Molly Chakraborty, et al.
Theranostics|April 25, 2017
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic SignificanceDavid Lh Chan, Nick Pavlakis, Geoffrey P Schembri, et al.
Pageof 18